Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
US5166195A · kind A · utility
180Cited by
1References
2Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | May 11, 1990 |
| Grant date | Nov 24, 1992 |
| Priority date | — |
| Expiry date | May 11, 2010 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16322
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for modulating the expression of the HIV tat gene are disclosed comprising contacting tat RNA with oligonucleotide or oligonucleotide analog which can bind with at least a portions of the RNA. In accordance with the preferred embodiments, oligonucleotides or oligonucleotide analogs are designed to bind to portions of the tat RNA which are of significance to the expression of the gene coding for said RNA. In accordance with a preferred embodiment, methods of treatment of human immunodeficiency virus are disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.